<DOC>
	<DOCNO>NCT02365662</DOCNO>
	<brief_summary>This open-label , Phase I , dose escalation study determine recommend Phase 2 dose , maximum tolerate dose , evaluate safety pharmacokinetic profile ABBV-221 participant advance solid tumor likely exhibit elevate level Epidermal Growth Factor Receptor ( EGFR ) .</brief_summary>
	<brief_title>A Study Evaluating Safety Pharmacokinetics ABBV-221 Subjects With Advanced Solid Tumor Types Likely Exhibit Elevated Levels Epidermal Growth Factor Receptor</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Has solid tumor likely exhibit elevate level EGFR ( e.g . head neck squamous cell carcinoma , nonsmall cell lung cancer , triple negative breast cancer , colorectal carcinoma glioblastoma multiforme ) . Has archive , diagnostic tumor tissue available analysis . Has adequate hematologic , renal , cardiac hepatic function . Expanded Safety Cohort participant must confirm metastatic lung cancer progress receive prior platinumcontaining chemotherapy . Previously receive EGFRdirected monoclonal antibody within past 4 week . Has unresolved , clinically significant toxicity prior anticancer therapy define &gt; Grade 1 Common Terminology Criteria Adverse Events . History major immunologic reaction IgG containing agent . Any medical condition opinion investigator place participant unacceptably high risk toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid Tumor type likely exhibit elevate level Epidermal Growth Factor Receptor</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Cancer</keyword>
	<keyword>Oncology</keyword>
</DOC>